Items where authors include "Ainsworth, G"

Article

Abbas, A, Schini, M, Ainsworth, G orcid.org/0000-0002-9952-8440 et al. (7 more authors) (2022) Effect of AZD4017, a Selective 11β-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal Osteopenia. Journal of Clinical Endocrinology and Metabolism. ISSN 0021-972X

Downey, CL, Croft, J orcid.org/0000-0001-7586-3394, Ainsworth, G orcid.org/0000-0002-9952-8440 et al. (5 more authors) (2020) Trial of remote continuous versus intermittent NEWS monitoring after major surgery (TRaCINg): a feasibility randomised controlled trial. Pilot and Feasibility Studies, 6 (1). 183. ISSN 2055-5784

Buckley, HL orcid.org/0000-0002-9829-5817, Collinson, FJ, Ainsworth, G et al. (15 more authors) (2019) PRISM protocol: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. BMC Cancer, 19. ARTN: 1102. ISSN 1471-2407

Collinson, F, Brown, S, Buckley, H orcid.org/0000-0002-9829-5817 et al. (11 more authors) (2018) PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. Annals of Oncology (Part of special issue:Abstract Book of the 43rd ESMO Congress (ESMO 2018) 19–23 October 2018, Munich, Germany), 29 (8). viii331-viii331. ISSN 0923-7534

Conference or Workshop Item

Vasudev, NS orcid.org/0000-0001-8470-7481, Ainsworth, G, Brown, S orcid.org/0000-0002-7975-7537 et al. (17 more authors) (2021) LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM). In: ESMO Congress 2021, 16-21 Sep 2021, Virtual.